A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy

Status: Recruiting

Eligibility Criteria

Sex: Male
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed adenocarcinoma of the prostate - treated by radical prostatectomy (RP) or radiotherapy (XRT) (including brachytherapy) or both with intention of cure - PSA has doubled in 12 months or less - normal testosterone level (greater than 150ng/dL) - must be able to walk, carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete inclusion & exclusion criteria

Exclusion Criteria:

evidence of metastatic disease in conventional CT scan and/or bone scan (positive on PSMA PET scan only is permitted) - prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide for prostate cancer - prior systemic biologic therapy, including immunotherapy, for prostate cancer - men with a female partner of childbearing potential or who are pregnant, who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 6 months after the last dose of xaluritamig

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), mCRPC, metastatic castration-resistant prostate cancer, Prostate Cancer

More Information

Description: This study is trying a new treatment (Xaluritamig) for men whose prostate cancer returned after the first treatment, but has not spread. The objective is to determine if Xaluritamig is safe and works well without causing negative side effects seen in other treatments. Participants will get Xaluritamig through a vein in their arm over six times with doctors observing for side effects and to see how the cancer reacts.
Study Contact: Skylar Mast - smast@umn.edu
Principal Investigator: Nicholas Zorko
Phase: PHASE1
IRB Number: STUDY00022748